IP Library Granted Patent US 7,091,354
Granted Patent B2
US 7,091,354 · App. 10/888,315 · Granted Aug 15, 2006

Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,091,354
App. No.
10/888,315
Granted
Aug 15, 2006
Kind
B2
Abstract

Novel processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto. The compounds prepared by the present processes may be useful, for example, as antagonists to the mu, kappa and delta opioid receptors, and thereby may be useful in the treatment of gastrointestinal motility disorders, and in preventing peripheral opiate induced side effects. The present processes may offer improved yields, purity, ease of preparation and/or isolation of intermediates and final product, and more industrially useful reaction conditions and workability.

Claims (27)

1. A process for preparing a compound of Formula Va, a compound of Formula Vb, or a mixture thereof:

wherein:

each R 1 is, independently, H, alkyl, aryl, or aralkyl;

each R 2 is, independently, H or a hydroxyl protecting group selected from the group consisting of alkyl, aryl, aralkyl alkylcarbonyl, arylcarbonyl, aralkylcarbonyl and silyl;

each R A is, independently, halo, alkyl, halo-substituted alkyl, alkenyl, alkynyl, aryl, OR, C(O)R, C(O)OR, OC(O)R, NHC(O)R, NHSO 2 R, SO 2 NRR, aminocarbonyl, amino, nitro, cyano, or SR, wherein each R is, independently, H, alkyl, aryl, or aralkyl; and

n is 0 to 5;

or a salt thereof;

comprising providing a compound of Formula IIa, a compound of Formula IIb, or a mixture thereof:

and substituting the secondary hydroxyl group of said compound of Formula IIa, said compound of Formula IIb, or said mixture thereof with hydrogen to provide the compound of Formula Va, the compound of Formula Vb, or the mixture thereof, wherein said substitution comprises hydrogenation, ionic dehydroxylation or radical deoxygenation.

2. A process of claim 1 wherein said compound of Formula IIa, said compound of Formula IIb, or said mixture thereof is provided by a process comprising contacting a compound of Formula III:

with a compound of Formula IVa:

at a temperature of from about −78° C. to about 150° C. for a period of time of from about 1 minute to about 7 days to provide said compound of Formula IIa, compound of Formula IIa, or mixture thereof.

3. A process of claim 1 wherein said substituting comprises:

(i) converting the secondary hydroxyl group of said compound of Formula IIa, said compound of Formula IIb, or said mixture thereof to a group having the formula —OR 3 ;

wherein each R 3 is, independently, a hydroxyl activating group selected from the group consisting of alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, C(S)O-aryl, C(S)O-alkyl, and silyl; and

(ii) substituting said —OR 3 group with hydrogen, wherein said substitution comprises hydrogenation, ionic dehydroxylation or radical deoxygenation.

4. A process of claim 1 wherein said substituting comprises:

(i) contacting said compound of Formula IIa, said compound of Formula IIb, or said mixture thereof with an activating reagent selected from the group consisting of an anhydride, an alcohol, an alkyl vinyl ether, and a silyl halide at a temperature of from about −78° C. to about 150° C. for a period of time of from about 1 minute to about 7 days to provide a compound of Formula VIa, a compound of Formula VIb, or a mixture thereof:

wherein each R 3 is, independently, a hydroxyl activating group selected from the group consisting of alkyl, aryl, aralkyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl C(S)O-aryl, C(S)O-alkyl, and silyl; and

(ii) contacting said compound of Formula VIa, said compound of Formula VIb, or said mixture thereof with said hydrogenating reagent to provide the compound of Formula Va, the compound of Formula Vb, or the mixture thereof.

5. A process of claim 4 wherein each R 2 is, independently, a hydroxyl protecting group.

6. A process of claim 5 further comprising removing said hydroxyl protecting group by base hydrolysis, acid hydrolysis, or hydrogenation.

7. A process of claim 4 wherein said activating reagent comprises Ac 2 O.

8. A process of claim 4 wherein said hydrogenating reagent comprises molecular hydrogen and a palladium catalyst.

9. A process of claim 4 wherein said hydroxyl activating group is, independently, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl C(S)O-aryl, or R z 3 Si—, wherein each R z is, independently, alkyl or aryl.

10. A process of claim 9 wherein said hydroxyl activating group is, independently, alkylcarbonyl.

11. A process of claim 10 wherein said hydroxyl activating group is —C(O)CH 3 .

Assignments (4)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2015
From: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
To: CALIXA THERAPEUTICS, INC.; ADOLOR CORPORATION; CUBIST PHARMACEUTICALS, INC.
Reel/Frame 036180/0070 →
NUNC PRO TUNC ASSIGNMENT Recorded Jul 9, 2015
From: ADOLOR CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 036046/0153 →
SECURITY AGREEMENT Recorded Nov 20, 2012
From: CUBIST PHARMACEUTICALS, INC.; ADOLOR CORPORATION; CALIXA THERAPEUTICS, INC.; CUBIST PHARMACEUTICALS HOLDINGS, INC.; CUBIST PHARMACEUTICALS U.S.
To: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
Reel/Frame 029339/0669 →